60 Degrees Pharmaceuticals, Inc.

SXTPW

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001946563

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $5.4M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data; fortress balan... not computable: dilution, distress
Inputs computable	5 of 14
Graded from	filings received through Mar 30, 2026 229 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$0.06 2026-02-09; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 76.4						
Gross profitability	4.2%	32.3%		86.1	365	2025-12-31
Return on invested capital	(335.2%)	9.3%		99.3	74	2025-12-31
Accruals ratio	(9.3%)	(6.6%)		43.7	799	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 3						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 71.9						
Twelve-month failure probability	not computable	0.08%				
firm-wide XBRL shares cannot be assigned to one ticker class						
Altman Z double-prime	(33.25)	(0.31)		83.1	743	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	2.66x	2.96x		60.7	825	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	not computable	2.3%				
four annual observations are required; found 3						
Net share issuance, one year	not computable	2.4%				
firm-wide XBRL shares cannot be assigned to one ticker class						

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 1.4 months
Thin data	5 of 14 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 1,360,065 USD; Altman Z is not used

What the price implies

at the 2026-02-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(53.3%)	(1.5%)	13
Distance from 52-week high	(78.4%)	(32.0%)	9
EBIT to enterprise value	not computable	(1.8%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.29	
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	(0.93)	(0.18)	13

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	pass

Cash, filings, liquidity

Cash and equivalents	$1.0M
Operating cash flow, four quarters	-$8.8M
Months of runway	1.4
Days since last periodic filing	92 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$15

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$223,776	2025-12-31	2026-03-30	10-K	26-000467
2	assets	us-gaap:Assets	$5.4M	2025-12-31	2026-03-30	10-K	26-000467
3	operating income	us-gaap:OperatingIncomeLoss	-$7.8M	2025-12-31	2026-03-30	10-K	26-000467
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$7.4M	2025-12-31	2026-03-30	10-K	26-000467
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-30	10-K	26-000467
6	total debt	us-gaap:LongTermDebt	$150,000	2025-12-31	2026-03-30	10-K	26-000467
7	book equity	us-gaap:StockholdersEquity	$3.5M	2025-12-31	2026-03-30	10-K	26-000467
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.5M	2025-12-31	2026-03-30	10-K	26-000467
9	total debt	us-gaap:LongTermDebt	$150,000	2024-12-31	2025-03-27	10-K	25-003343
10	book equity	us-gaap:StockholdersEquity	$4.0M	2024-12-31	2026-03-30	10-K	26-000467
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.7M	2024-12-31	2026-03-30	10-K	26-000467
12	net income	us-gaap:NetIncomeLoss	-$7.4M	2025-12-31	2026-03-30	10-K	26-000467
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$6.8M	2025-12-31	2026-03-30	10-K	26-000467
14	assets	us-gaap:Assets	$5.8M	2024-12-31	2026-03-30	10-K	26-000467
15	current assets	us-gaap:AssetsCurrent	$4.9M	2025-12-31	2026-03-30	10-K	26-000467
16	current liabilities	us-gaap:LiabilitiesCurrent	$1.8M	2025-12-31	2026-03-30	10-K	26-000467
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$47.9M	2025-12-31	2026-03-30	10-K	26-000467
18	liabilities	us-gaap:Liabilities	$2.0M	2025-12-31	2026-03-30	10-K	26-000467
19	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$43,324	2025-12-31	2026-03-30	10-K	26-000467
20	operating income	us-gaap:OperatingIncomeLoss	-$5.2M	2023-12-31	2025-03-27	10-K	25-003343
21	interest expense	us-gaap:InterestExpense	$2.3M	2023-12-31	2024-04-01	10-K	24-028577
22	revenue	us-gaap:Revenues	$1.0M	2025-12-31	2026-03-30	10-K	26-000467
23	revenue	us-gaap:Revenues	$607,574	2024-12-31	2026-03-30	10-K	26-000467
24	revenue	us-gaap:Revenues	$253,573	2023-12-31	2025-03-27	10-K	25-003343
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$139,881	2025-12-31	2026-03-30	10-K	26-000467
26	current assets	us-gaap:AssetsCurrent	$5.4M	2024-12-31	2026-03-30	10-K	26-000467
27	current liabilities	us-gaap:LiabilitiesCurrent	$1.7M	2024-12-31	2026-03-30	10-K	26-000467
28	assets	us-gaap:Assets	$7.8M	2023-12-31	2025-03-27	10-K	25-003343

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.